Latest News
John Lewis of Hungerford anticipates 'small' FY pre-tax profits
Retailer John Lewis of Hungerford said on Thursday that its second-half performance had exceeded expectations, with profits now expected to recover the loss recorded by the group in the first half and lead to a "small" full-year pre-tax profit.
Keywords Studios acquires video game art studio AMC
Video games services provider Keywords Studios has acquired video game art creation studio AMC for €2. 8m.
Abingdon Health FY revenues at bottom end of guidance
Covid-19 test kit manufacturer Abingdon Health warned on Thursday that full-year revenues would be at the bottom end of forecasts.
Asia reports: Markets fall after dollar weakens, Li Auto disappoints
Sharemarkets were lower at the close in Asia on Thursday, as investors monitored a weaker dollar, with Chinese electric vehicle producer Li Auto disappointing on its debut day.
UK regulator may force Facebook to unwind Giphy purchase
The UK's competition regulator said it may require Facebook to unwind its purchase of Giphy because the tie-up threatens to reduce competition between social media platforms.
US close: Dow Jones adds slight gains to record high
Wall Street stocks closed higher on Thursday as market participants thumbed over this week's jobless report and July's producer price index.
Moderna vaccine offers double the protection against breakthrough Covid-19 infection
Moderna's Covid-19 vaccine offers nearly twice the protection against so-called breakthrough infections than Pfizer's, a new study found.
Friday preview: US consumer confidence in focus
Friday's main economic data release will be a preliminary reading on the University of Michigan's US consumer confidence index in July.
Europe close: Stocks continue to grind higher
European stocks were mostly higher again on Thursday as strong corporate news from insurers offset a fall in stocks going ex-dividend.
Philip Morris wins takeover battle for inhaler maker Vectura
US tobacco giant Philip Morris has won the battle for London-listed inhaler maker Vectura.
London close: Stocks weaker as Rio Tinto drags on FTSE
London equities closed below the waterline on Thursday, with ex-dividend stocks proving to be a drag as investors digested the latest UK GDP reading.
McColl's tanks as it warns on profits, confirms cash call
McColl’s shares tanked on Thursday after the convenience retailer warned that its full-year performance could fall short of management expectations due to availability issues, and confirmed plans for a £35m equity raise.
Broker tips: Ferguson, Hill & Smith
Deutsche Bank lifted its price target on Ferguson to 11,800. 0p from 10,100. 0p on Thursday as it pointed to further upside from growth in the US housing market and economy.
San Leon announces progress at Decklar
Nigeria-focussed oil and gas exploration, development and production company San Leon noted an announcement from Decklar Resources on Thursday, having entered into a conditional subscription agreement with Decklar Petroleum - the local subsidiary of Decklar Resources.
Director dealings: Kainos' Paul Gannon lowers stake
Kainos Group revealed on Thursday that senior vice president of business development Paul Gannon had disposed of 200,000 ordinary shares in the FTSE 250-listed software firm.
FDA may be set to announce booster shots for immunocompromised
America's health regulator is close to recommending that so-called booster shots be given to certain people with weak immune systems.
US producer prices rise more quickly than expected in July
US producer prices rose more quickly than anticipated last month due to the higher cost of energy and transportation.
Reddit will raise up to $700m in fresh financing
Reddit is set to tap investors for $700m in fresh capital with the help of Fidelity Management.
Arqiva to sell remaining operations - report
UK telecommunications company Arqiva is reportedly preparing to sell its remaining operations, which could be valued at around £2. 5bn.
JP Morgan restarts AstraZeneca at overweight, sees re-rating opportunity
Analysts at JP Morgan resumed their coverage of AstraZeneca at 'overweight', telling clients they saw a "re-rating opportunity".
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.